@article{JTD31841,
author = {Guanghui Gao and Meng Qiao and Hongcheng Liu and Tao Jiang and Fei Zhou and Xuefei Li and Chao Zhao and Xiaoxia Chen and Chunxia Su and Shengxiang Ren and Caicun Zhou},
title = {Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {9},
year = {2019},
keywords = {},
abstract = {Background: To investigate the impact of different immune checkpoint inhibitors (ICI), programmed-death ligand 1 (PD-L1) expression and clinical characteristics on clinical outcome of ICI plus conventional treatment in advanced lung cancer patients.
Methods: Randomized clinical trials that compared combination therapy versus control group were screened in PubMed, EMBASE, Web of Science, Cochrane Library and included. The pooled hazard ratio (HR) with a 95% confidence interval (95% CI) were used to estimate associations. Cochrane Collaboration tool was used for quality assessment.
Results: Thirteen clinical trials were included (n=9,241). The pooled results indicated that combination strategy based on ICI significantly improved PFS (HR =0.66, P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/31841}
}